KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBITDA Margin (2016 - 2025)

Nektar Therapeutics has reported EBITDA Margin over the past 16 years, most recently at 126.86% for Q4 2025.

  • Quarterly results put EBITDA Margin at 126.86% for Q4 2025, down 17604.0% from a year ago — trailing twelve months through Dec 2025 was 253.66% (down 14678.0% YoY), and the annual figure for FY2025 was 253.66%, down 14678.0%.
  • EBITDA Margin for Q4 2025 was 126.86% at Nektar Therapeutics, up from 268.63% in the prior quarter.
  • Over the last five years, EBITDA Margin for NKTR hit a ceiling of 49.18% in Q4 2024 and a floor of 708.07% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 257.74% (2025), compared with a mean of 310.79%.
  • Biggest five-year swings in EBITDA Margin: tumbled -31906bps in 2022 and later surged 46123bps in 2023.
  • Nektar Therapeutics' EBITDA Margin stood at 451.48% in 2021, then skyrocketed by 47bps to 238.25% in 2022, then surged by 41bps to 140.3% in 2023, then surged by 135bps to 49.18% in 2024, then plummeted by -358bps to 126.86% in 2025.
  • The last three reported values for EBITDA Margin were 126.86% (Q4 2025), 268.63% (Q3 2025), and 324.21% (Q2 2025) per Business Quant data.